87 related articles for article (PubMed ID: 7658292)
1. Benefit-cost analysis of drug abuse prevention programs: a macroscopic approach.
Kim S; Coletti SD; Crutchfield CC; Williams C; Hepler N
J Drug Educ; 1995; 25(2):111-27. PubMed ID: 7658292
[TBL] [Abstract][Full Text] [Related]
2. Organizational and client determinants of cost in outpatient substance abuse treatment.
Beaston-Blaakman A; Shepard D; Horgan C; Ritter G
J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043
[TBL] [Abstract][Full Text] [Related]
3. Estimating the economic cost of substance abuse treatment.
French MT; McGeary KA
Health Econ; 1997; 6(5):539-44. PubMed ID: 9353658
[TBL] [Abstract][Full Text] [Related]
4. Applying benefit-cost analysis to substance use prevention programs.
Plotnick RD
Int J Addict; 1994 Feb; 29(3):339-59. PubMed ID: 8188432
[TBL] [Abstract][Full Text] [Related]
5. Substance abuse treatment services: an introduction.
Lowman C
J Ment Health Adm; 1992; 19(1):1-4. PubMed ID: 10171033
[No Abstract] [Full Text] [Related]
6. Effectiveness and cost-effectiveness of four treatment modalities for substance disorders: a propensity score analysis.
Mojtabai R; Zivin JG
Health Serv Res; 2003 Feb; 38(1 Pt 1):233-59. PubMed ID: 12650390
[TBL] [Abstract][Full Text] [Related]
7. Insights from a national survey into why substance abuse treatment units add prevention and outreach services.
Wells R; Lemak CH; D'Aunno TA
Subst Abuse Treat Prev Policy; 2006 Aug; 1():21. PubMed ID: 16887037
[TBL] [Abstract][Full Text] [Related]
8. The cost and cost-effectiveness of an enhanced intervention for people with substance abuse problems at risk for HIV.
Zarkin GA; Lindrooth RC; Demiralp B; Wechsberg W
Health Serv Res; 2001 Jun; 36(2):335-55. PubMed ID: 11409816
[TBL] [Abstract][Full Text] [Related]
9. Improving cost-effectiveness in a substance abuse treatment program.
Francis E; Hughes P; Schinka J
Psychiatr Serv; 1999 May; 50(5):633-5. PubMed ID: 10332897
[No Abstract] [Full Text] [Related]
10. Benefit-cost analysis of addiction treatment: methodological guidelines and empirical application using the DATCAP and ASI.
French MT; Salomé HJ; Sindelar JL; McLellan AT
Health Serv Res; 2002 Apr; 37(2):433-55. PubMed ID: 12036002
[TBL] [Abstract][Full Text] [Related]
11. A profile of the substance abuse treatment industry: organization, costs, and treatment completion.
Woodward AM; Raskin IE; Blacklow B
Subst Use Misuse; 2008; 43(5):647-79. PubMed ID: 18393082
[TBL] [Abstract][Full Text] [Related]
12. Drug treatment takes a hit. As substance abuse has surged among teens, coverage for care has been curtailed.
Gardner J
Mod Healthc; 1996 Oct; 26(43):66, 68, 70-2. PubMed ID: 10172795
[No Abstract] [Full Text] [Related]
13. Costs and benefits of combining probation and substance abuse treatment.
Alemi F; Taxman F; Baghi H; Vang J; Thanner M; Doyon V
J Ment Health Policy Econ; 2006 Jun; 9(2):57-70. PubMed ID: 17007484
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of family-based substance abuse treatment.
Morgan TB; Crane DR
J Marital Fam Ther; 2010 Oct; 36(4):486-98. PubMed ID: 21039660
[TBL] [Abstract][Full Text] [Related]
15. Utilization and costs of substance abuse services within The HMO Group.
Levin BL
HMO Pract; 1993 Mar; 7(1):28-34. PubMed ID: 10171407
[TBL] [Abstract][Full Text] [Related]
16. Prevention validation and accounting platform: a framework for establishing accountability and performance measures of substance abuse prevention programs.
Kim S; McLeod JH; Williams C; Hepler N
J Drug Educ; 2000; 30(1):1-143. PubMed ID: 10893910
[TBL] [Abstract][Full Text] [Related]
17. Benefits and costs associated with mutual-help community-based recovery homes: The Oxford House model.
Lo Sasso AT; Byro E; Jason LA; Ferrari JR; Olson B
Eval Program Plann; 2012 Feb; 35(1):47-53. PubMed ID: 22054524
[TBL] [Abstract][Full Text] [Related]
18. Guidelines and challenges for estimating the economic costs and benefits of adolescent substance abuse treatments.
Zavala SK; French MT; Henderson CE; Alberga L; Rowe C; Liddle HA
J Subst Abuse Treat; 2005 Oct; 29(3):191-205. PubMed ID: 16183468
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and benefit-cost of peer-based workplace substance abuse prevention coupled with random testing.
Miller TR; Zaloshnja E; Spicer RS
Accid Anal Prev; 2007 May; 39(3):565-73. PubMed ID: 17125723
[TBL] [Abstract][Full Text] [Related]
20. Estimating the dollar value of health outcomes from drug-abuse interventions.
French MT; Mauskopf JA; Teague JL; Roland EJ
Med Care; 1996 Sep; 34(9):890-910. PubMed ID: 8792779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
